Positron emission tomography-computed tomography for imaging of inflammatory cardiovascular diseases - Sarcoidosis, large-vessel arteritis, and atherosclerosis -

Circulation Journal

Volumn 78, Issue 6, 2014, Pages 1302-1310

  Miyagawa, Masao ^a   Yokoyama, Rami ^a   Nishiyama, Yoshiko ^a   Ogimoto, Akiyoshi ^a   Higaki, Jitsuo ^a   Mochizuki, Teruhito ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Cardiac sarcoidosis; Inflammation; Large vessel arteritis; Positron emission tomography computed tomography (PET CT) imaging

Indexed keywords

CD68 ANTIGEN; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEPARIN; HEXOKINASE; RADIOPHARMACEUTICAL AGENT;

AORTA ARCH SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR INFLAMMATION; CAUSE OF DEATH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; HEART MUSCLE BIOPSY; HUMAN; INFECTION; LOW DRUG DOSE; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; REVIEW; RISK; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUDDEN DEATH; VASCULITIS; VIRUS MYOCARDITIS; ANIMAL; ARTERITIS; HEALTH INSURANCE; HEART DISEASE; JAPAN; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIOGRAPHY;

ANIMALS; ARTERITIS; ATHEROSCLEROSIS; FLUORODEOXYGLUCOSE F18; HEART DISEASES; HUMANS; INSURANCE, HEALTH; JAPAN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOIDOSIS;

EID: 84901346288     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0250     Document Type: Review

References (76)

1. Shepherd PR, Kahn BB. Glucose transporters and insulin action, implications for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341: 248-257.
2. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry. J Clin Oncol 2008; 26: 2155-2161.
3. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lamertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47: 1059-1066.
4. Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 2013; 54: 647-658.
5. 18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002; 105: 2708-2711.
6. 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 2005; 36: 2642-2647.
7. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-1831.
8. James OG, Christensen JD, Wong TZ, Borges-Neto S, Koweek LM. Utility of FDG PET/CT in inflammatory cardiovascular disease. Radiographics 2011; 31: 1271-1286.
9. 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. Int J Radiat Oncol Biol Phys 2006; 66: 845-851.
10. Zöphel K, Hölzel C, Dawel M, Hölscher T, Evers C, Kotzerke J. PET/CT demonstrates increased myocardial FDG uptake following irradiation therapy. Eur J Nucl Med Mol Imaging 2007; 34: 1322-1323.
11. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010; 102: 14-25.
12. Miyagawa M, Tanada S, Hamamoto K. Scintigraphic evaluation of myocardial uptake of thallium-201 and technetium-99 m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity. Eur J Nucl Med 1991; 18: 332-338.
13. Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005; 111: 887-893.
14. Takano H, Nakagawa K, Ishio N, Daimon M, Daimon M, Kobayashi Y, et al. Active myocarditis in a patient with chronic active Epstein-Barr virus infection. Int J Cardiol 2008; 130: e11-e13, doi: 10. 1016/j. ijcard. 2007. 07. 040.
15. 18F-FDG PET in the diagnosis of cardiac sarcoidosis, a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53: 241-248.
16. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis: American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-173.
17. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58: 1204-1211.
18. Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann NY Acad Sci 1976; 278: 455-469.
19. Iwai K, Sekiguti M, Hosoda Y, DeRemee RA, Tazelaar HD, Sharma OP, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994; 11: 26-31.
20. Iannuzzi MC, Fontana JR. Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-399.
21. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: Evaluation of endomyocardial biopsies. Am Heart J 1999; 138: 299-302.
22. Lorell B, Alderman EL, Mason JW. Cardiac sarcoidosis: Diagnosis with endomyocardial biopsy and treatment with corticosteroids. Am J Cardiol 1978; 42: 143-146.
23. Ishikawa T, Kondoh H, Nakagawa S, Koiwaya Y, Tanaka K. Steroid therapy in cardiac sarcoidosis: Increased left ventricular contractility concomitant with electrocardiographic improvement after prednisolone. Chest 1984; 85: 445-447.
24. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88: 1006-1010.
25. Hiraga H, Iwai K, Hiroe M. Guidelines for diagnosis of cardiac sarcoidosis, study report on diffuse pulmonary diseases. Tokyo: The Japanese Ministry of Health and Welfare, 1993; 23-24 (in Japanese).
26. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disorders 2007; 27: 89-102 (in Japanese).
27. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis, with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009; 20: 578-583.
28. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with (13)NNH(3)/(18) F-FDG PET. J Nucl Med 2003; 44: 1030-1036.
29. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45: 1989-1998.
30. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26: 1538-1543.
31. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009; 16: 801-810.
32. Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010; 3: 1219-1228.
33. 18F-fluorodoexyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis. Eur J Nucl Med Mol Imaging 2013; 40: 1558-1566.
34. 18F-fluorodoexyglucose positron emission tomography? Circ Cardiovasc Imaging 2013; 6: 617-626.
35. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63: 329-336.
36. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: A Delphi study. Chest 2012; 141: 154-162.
37. Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med 2014; 55: 99-106.
38. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120: 1969-1977.
39. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35: 933-941.
40. Casset-Senon D, Philippe L, Renard JP, Cosnay P. Recurrent ventricular tachycardia in cardiac sarcoidosis: Usefulness of fluorodeoxyglucose positron emission tomography for adequate management of corticoid therapy after placement of an implantable cardioverter defibrillator. J Nucl Cardiol 2008; 15: 282-285.
41. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36: 1301-1306.
42. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001; 42: 1551-1555.
43. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992; 89: 1767-1774.
44. Fox JJ, Strauss HW. One step closer to imaging vulnerable plaque in the coronary arteries. J Nucl Med 2009; 50: 497-500.
45. Simoes MV, Egert S, Ziegler S, Miyagawa M, Reder S, Lehner T, et al. Delayed response of insulin-stimulated fluorine-18 deoxyglucose uptake in glucose transporter-4-null mice hearts. J Am Coll Cardiol 2004; 43: 1690-1697.
46. 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009; 50: 563-568.
47. Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol 2011; 18: 926-936.
48. Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A doseresponse study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol 1979; 7: 531-533.
49. Persson E. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity: Effects of heparin and a low molecular weight heparin fragment (Fragmin). Acta Med Scand Suppl 1988; 724: 1-56.
50. 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990; 322: 223-228.
51. 18F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology Recommendations. Ann Nucl Med 2014 January 25, doi: 10. 1007/s12149-014-0806-0.
52. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 539-542.
53. Brodmann M, Lipp RW, Passath A, Seinost G, Pabst E, Pilger E. The role of 2-18F-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology 2004; 43: 241-242.
54. Ohira H, McArdle B, Cocker MS, deKemp RA, DaSilva JN, Beanlands RS. Current and future clinical applications of cardiac positron emission tomography. Circ J 2013; 77: 836-848.
55. 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48: 1818-1824.
56. 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med 2007; 48: 227-233.
57. 18F-FDG imaging of human atherosclerotic carotid plaques reflects gene expression of the key hypoxia marker HIF-1α. Am J Nucl Med Mol Imaging 2013; 3: 384-392.
58. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009; 50: 1611-1620.
59. Noh TS, Moon SH, Cho YS, Hong SP, Lee EJ, Choi JY, et al. Relation of carotid artery 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymptomatic adults. J Nucl Med 2013; 54: 2070-2076.
60. Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffman U, Vermylen DA, et al. Feasibility of FDG imaging of the coronary arteries: Comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging 2010; 3: 388-397.
61. 18F]-Fluorodeoxyglucose, a new imaging modality for atherosclerotic plaque thrombogenicity. Circ J 2013; 77: 2479-2480.
62. Ben Haim S, Kupzov E, Tamir A, Frenkel A, Israel O. Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. J Nucl Cardiol 2006; 13: 791-800.
63. Wassélius J, Larsson S, Jacobsson H. Time-to-time correlation of high-risk atherosclerotic lesions identified with [(18)F]-FDG-PET/CT. Ann Nucl Med 2009; 23: 59-64.
64. Ohigashi H, Haraguchi G, Konishi M, Tezuka D, Kamiishi T, Ishihara T, et al. Improved prognosis of Takayasu arteritis over the past decade: Comprehensive analysis of 106 patients. Circ J 2012; 76: 1004-1011.
65. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-1134.
66. Theron J, Tyler JL. Takayasu's arteritis of the aortic arch: Endovascular treatment and correlation with positron emission tomography. Am J Neuroradiol 1987; 8: 621-626.
67. Hautzel H, Sander O, Heinzel A, Schneider M, Müller HW. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: Introducing an ROC-analysis-based cutoff ratio. J Nucl Med 2008; 49: 1107-1113.
68. Webb M, Chambers A, Al-Nahhas A, Mason JC, Maudlin L, Rahman L, et al. The role of F-18-FDG-PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 2004; 31: 627-634.
69. Kobayashi Y, Ishii K, Oda K, Nariai T, Tanaka Y, Ishiwata K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18FFDG PET coregistered with enhanced CT. J Nucl Med 2005; 46: 917-922.
70. Murakami M, Morikage N, Samura M, Yamashita O, Suehiro K, Hamano K. Fluorine-18-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis of infected aortic aneurysms. Ann Vasc Surg 2014; 28: 575-578.
71. 18F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis. Nat Med 2014; 20: 215-219.
72. 68Ga-DOTATATE PET/CT: Correlation with coronary calcium burden and risk factors. J Nucl Med 2010; 51: 193-197.
73. Derlin T, Tóth Z, Papp L, Wisotzki C, Apostolova I, Habermann CR, et al. Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-Fluoride PET, and vascular calcification in atherosclerotic plaque, a dual-tracer PET/CT study. J Nucl Med 2011; 52: 1020-1027.
74. Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18F-sodium fluoride uptake: A novel marker of plaque biology. J Am Coll Cardiol 2012; 59: 1539-1548.
75. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques, a prospective clinical trial. Lancet 2014; 383: 705-713.
76. Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: Potential, initial experiences, and future prospects. J Nucl Med 2013; 54: 402-415.